Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab209861-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$109.90
|
|
|
Ab209861-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$519.90
|
|
|
Ab209861-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,299.90
|
|
|
Ab209861-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,079.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Varisacumab (anti-VEGF) - Primary antibody, specific to VEGFA, Human IgG1 |
|---|---|
| Synonyms | Folliculostellate cell-derived growth factor antibody | Glioma-derived endothelial cell mitogen antibody | MGC70609 antibody | MVCD1 antibody | Vascular endothelial growth factor A antibody | vascular endothelial growth factor A121 antibody | vascular end |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 re |
| Host species | Human |
| Specificity | VEGFA |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Varisacumab (anti-VEGF) is a human recombinant monoclonal antibody targeting VEGFA. It may be used in research of Microvascular complications of diabetes 1 (MVCD1). |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1610010-60-0 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Varisacumab (anti-VEGF) (Ab209861) - ELISA
Immobilized Recombinant Human VEGF protein (rp155965) at 1.0 μg/mL can bind Varisacumab (anti-VEGF) (Ab209861) with the EC₅₀ of 15.80 ng/mL.
Varisacumab (anti-VEGF) (Ab209861) - SEC
The purity of Varisacumab (anti-VEGF) (Ab209861) is more than 95% verified by HPLC.
Starting at $66.90
Starting at $59.90
Starting at $66.90
Starting at $66.90